Jiangsu Hualv Biological Technology Co.Ltd. Net Assets
Jiangsu Hualv Biological Technology Co.Ltd. net assets. Based on the latest financial reports, Jiangsu Hualv Biological Technology Co.Ltd. (300970) has net assets worth CN¥1.68 Billion CNY (≈ $245.25 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.60 Billion ≈ $379.87 Million USD) and total liabilities (CN¥919.95 Million ≈ $134.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Jiangsu Hualv Biological Technology Co.L (300970) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.68 Billion |
| % of Total Assets | 64.56% |
| Annual Growth Rate | 14.62% |
| 5-Year Change | 16.3% |
| 10-Year Change | N/A |
| Growth Volatility | 24.05 |
Net Assets of Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
Net assets of Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025. This chart illustrates how Jiangsu Hualv Biological Technology Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Jiangsu Hualv Biological Technology Co.L to measure how much of total assets are equity-financed.
Annual Net Assets for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
The table below shows the annual net assets of Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025. For live market cap and overall valuation, see market cap of Jiangsu Hualv Biological Technology Co.L.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.67 Billion ≈ $244.65 Million |
+10.04% |
| 2024-12-31 | CN¥1.52 Billion ≈ $222.33 Million |
-3.10% |
| 2023-12-31 | CN¥1.57 Billion ≈ $229.44 Million |
+2.98% |
| 2022-12-31 | CN¥1.52 Billion ≈ $222.80 Million |
+5.91% |
| 2021-12-31 | CN¥1.44 Billion ≈ $210.37 Million |
+68.92% |
| 2020-12-31 | CN¥851.05 Million ≈ $124.54 Million |
+15.44% |
| 2019-12-31 | CN¥737.21 Million ≈ $107.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Hualv Biological Technology Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 52.9% over the analyzed period, indicating profitable operations and earnings retention.
Jiangsu Hualv Biological Technology Co.Ltd. Net Assets Breakdown (December 2025)
Jiangsu Hualv Biological Technology Co.Ltd. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥547.98 Million | 33.48% |
| Other Components | CN¥1.09 Billion | 66.52% |
| Total Equity | CN¥1.64 Billion | 100.00% |
Jiangsu Hualv Biological Technology Co.Ltd. Competitors by Market Cap
The table below lists competitors of Jiangsu Hualv Biological Technology Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coremax Corp
TW:4739
|
$281.97 Million |
|
Socep Constant
RO:SOCP
|
$282.03 Million |
|
TianJin JinRong TianYu Precision Machinery Inc.
SHE:300988
|
$282.08 Million |
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
$282.11 Million |
|
Shenwu Energy Saving Co Ltd
SHE:000820
|
$281.94 Million |
|
Tehmag Foods
TWO:1264
|
$281.91 Million |
|
Everyday Network
SHE:300295
|
$281.90 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
$281.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Hualv Biological Technology Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,492,022,748 to 1,636,902,542, a change of 144,879,794 (9.7%).
- Net income of 110,268,302 contributed positively to equity growth.
- Dividend payments of 11,536,850 reduced retained earnings.
- Other factors increased equity by 46,148,342.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥110.27 Million | +6.74% |
| Dividends Paid | CN¥11.54 Million | -0.7% |
| Other Changes | CN¥46.15 Million | +2.82% |
| Total Change | CN¥- | 9.71% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Hualv Biological Technology Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.43x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥8.42 | CN¥12.05 | x |
| 2020-12-31 | CN¥9.69 | CN¥12.05 | x |
| 2021-12-31 | CN¥12.24 | CN¥12.05 | x |
| 2022-12-31 | CN¥9.96 | CN¥12.05 | x |
| 2023-12-31 | CN¥10.10 | CN¥12.05 | x |
| 2024-12-31 | CN¥9.55 | CN¥12.05 | x |
| 2025-12-31 | CN¥10.27 | CN¥12.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Hualv Biological Technology Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.74%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.54%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.51x
- Recent ROE (6.74%) is above the historical average (6.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 16.37% | 20.97% | 0.57x | 1.38x | CN¥46.95 Million |
| 2020 | 15.63% | 21.74% | 0.52x | 1.37x | CN¥47.72 Million |
| 2021 | 1.09% | 2.68% | 0.31x | 1.31x | CN¥-127.39 Million |
| 2022 | 5.18% | 10.41% | 0.38x | 1.31x | CN¥-72.78 Million |
| 2023 | 1.96% | 3.05% | 0.47x | 1.37x | CN¥-124.42 Million |
| 2024 | -3.19% | -4.61% | 0.45x | 1.55x | CN¥-196.77 Million |
| 2025 | 6.74% | 8.54% | 0.52x | 1.51x | CN¥-53.42 Million |
Industry Comparison
This section compares Jiangsu Hualv Biological Technology Co.Ltd.'s net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $912,217,488
- Average return on equity (ROE) among peers: 12.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Hualv Biological Technology Co.Ltd. (300970) | CN¥1.68 Billion | 16.37% | 0.55x | $281.96 Million |
| ShenZhen Kondarl Group Co Ltd (000048) | $341.57 Million | 10.73% | 1.99x | $1.05 Billion |
| Guangdong Guanghong Holdings Co Ltd (000529) | $3.17 Billion | 6.71% | 1.21x | $391.26 Million |
| Hunan Zhenghong Science and Technology Develop Co Ltd (000702) | $300.43 Million | -21.72% | 1.35x | $249.55 Million |
| Hefei Fengle Seed Co Ltd (000713) | $1.12 Billion | 8.62% | 0.69x | $634.25 Million |
| Luoniushan Co Ltd (000735) | $418.09 Million | 11.68% | 0.34x | $850.94 Million |
| New Hope Liuhe Co Ltd (000876) | $1.84 Billion | 6.76% | 0.76x | $4.67 Billion |
| Yuan Longping High-tech Agriculture Co Ltd (000998) | $87.24 Million | 31.20% | 1.05x | $1.74 Billion |
| Dongrui Food Group Co Ltd (001201) | $569.61 Million | 45.97% | 0.50x | $584.69 Million |
| Jiangxi Sunshine Dairy Co Ltd (001318) | $585.62 Million | 19.17% | 0.10x | $589.82 Million |
| Shandong Denghai Seeds Co Ltd (002041) | $694.16 Million | 0.82% | 0.25x | $1.13 Billion |
About Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.